article thumbnail

Hormone therapy linked to tau accumulation in older women

AuntMinnie

A PET study has revealed that women over the age of 70 who took menopausal hormone therapy (HT) more than a decade before have faster brain tau accumulation -- a key indicator of Alzheimers disease. The findings may inform [Alzheimers disease] risk discussions relating to womens reproductive health and treatment, the group wrote.

Disease 162
article thumbnail

Brainomix, Boehringer Ingelheim partner on improving lung disease care

AuntMinnie

AI imaging firm Brainomix has entered into a partnership with German pharmaceutical company Boehringer Ingelheim to improve the care of U.S. patients with fibrosing lung disease.

Disease 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How AI is Transforming the Pharmaceutical Industry

MRI Network

It’s also primed to revolutionize the pharmaceutical industry. Pharma companies that truly embrace AI can run parallel clinical trials for the same drug as a single agent or in combinations targeting multiple diseases where the drug is predicted to work. Many pharma companies have changed their CEOs at least once.

article thumbnail

Radiotracer for kidney cancer performs well in phase III trial

AuntMinnie

The imaging agent fills an unmet need to identify small lesions, which could allow earlier diagnosis of the disease, noted lead author Brian Shuch, MD, of the University of California, Los Angeles, and colleagues.

article thumbnail

Telix inks distribution deal for Zircaix

AuntMinnie

Telix Pharmaceuticals has selected Cardinal Health to distribute its PET agent TLX250-CDx (Zircaix) for imaging kidney cancer in the U.S., In a recent phase III trial , the radiotracer was shown to be safe and effective for identifying small lesions, which could allow for earlier diagnosis of the disease. the company noted.

article thumbnail

Enigma Biomedical inks deal to develop tau PET biomarkers

AuntMinnie

Enigma Biomedical Group USA (EBG-USA) has signed an exclusive agreement to commercialize AbbVie’s tau PET imaging biomarkers for use in patients with suspected neurodegenerative disease. If the evaluations are favorable, EBG-USA has the option to negotiate an exclusive license agreement with AbbVie for the PET ligands.

article thumbnail

FDA fast-tracks Clarity’s prostate cancer treatment

AuntMinnie

Clarity Pharmaceuticals has secured fast-track designation from the U.S. The classification builds on Clarity's earlier receipt of fast-track designation for its PET diagnostic imaging agent Cu-64 SAR-bisPSMA for identifying patients with the disease.